{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:01:11Z","timestamp":1771938071583,"version":"3.50.1"},"reference-count":32,"publisher":"Pensoft Publishers","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FM"],"abstract":"<jats:p>\n                    <jats:bold>Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Introduction<\/jats:bold>\n                    : Fosinopril sodium, an angiotensin-converting enzyme inhibitor, is a widely prescribed antihypertensive agent and one of the leading drugs approved for use in hypertension management. Despite its clinical relevance, no UV-spectrophotometric methods have been previously reported for the analysis of fosinopril sodium in simulated salivary fluid (SSF, pH 6.8) and simulated gastric fluid (SGF, pH 1.2). However, researchers favor UV-spectrophotometry due to its versatility, simplicity, and efficiency in drug analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Aim<\/jats:bold>\n                    : The aim of this study was to develop and validate a simple, rapid, and cost-effective UV-spectrophotometric method for analyzing fosinopril sodium in both experimental and commercial dosage forms, as well as in novel drug delivery systems.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Materials and methods<\/jats:bold>\n                    : This study presents the development of a UV-spectrophotometric method for quantifying fosinopril sodium in enzyme-free SSF and SGF media and its validation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : Maximum absorbance is observed at 209 nm in SSF and 207 nm in SGF. The technique demonstrates linearity in the range of 2.5\u201320 \u03bcg\/mL, with a limit of detection and limit of quantification of 0.0438 \u03bcg\/mL and 0.133 \u03bcg\/mL in SSF, and 0.0714 \u03bcg\/mL and 0.216 \u03bcg\/mL in SGF, respectively. Analytical recovery is 100.1% in SSF and 99.9% in SGF, with RSD values of 0.373% in SSF and 0.203% in SGF, indicating high precision and accuracy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : These results demonstrate that the developed and validated method is suitable for the routine quantitative determination of fosinopril sodium in experimental and commercial pharmaceutical formulations.\n                  <\/jats:p>","DOI":"10.3897\/folmed.68.e169306","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:07:48Z","timestamp":1771934868000},"source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a UV-spectrophotometric method for determination of an ACE inhibitor in pharmaceutical formulations"],"prefix":"10.3897","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7622-6060","authenticated-orcid":true,"given":"Yana","family":"Gvozdeva","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Medical University of Plovdiv, Plovdiv, Bulgaria"},{"name":"Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria"},{"name":"Center for Competence \u201cPERIMED-2\u201d, Medical University of Plovdiv, Plovdiv, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2258","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"169306_B1","doi-asserted-by":"crossref","unstructured":"Mashru R, Sutariya V, Thakker A. Spectrophotometric analysis of fosinopril sodium in pure form and tablets. Indian J Pharm Sci 2006; 68(5):643.","DOI":"10.4103\/0250-474X.29636"},{"key":"169306_B2","doi-asserted-by":"crossref","unstructured":"Parvatamma B, Rao TN, Patrudu TB, et al. A new high-performance liquid chromatographic method for identification and quantification of fosinopril sodium and its related impurities in bulk drug product. Asian J Pharm Res 2017; 7(3):165\u201370.","DOI":"10.5958\/2231-5691.2017.00025.9"},{"key":"169306_B3","doi-asserted-by":"crossref","unstructured":"Udrescu L, Sb\u00e2rcea L, Fulia\u0219 A, et al. Physicochemical analysis and molecular modeling of the fosinopril \u03b2-cyclodextrin inclusion complex. J Spectrosc 2014; 2014:1\u201314.","DOI":"10.1155\/2014\/748468"},{"key":"169306_B4","doi-asserted-by":"crossref","unstructured":"Kostis JB, Garland WT, Delaney C, et al. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. Clin Pharmacol Ther 1995; 58(6):660\u20135.","DOI":"10.1016\/0009-9236(95)90022-5"},{"key":"169306_B5","doi-asserted-by":"crossref","unstructured":"Khashaba P, Mohamed H, Shahin R. Analysis of angiotensin converting enzyme inhibitors and antagonists. Sphinx J Pharm Med Sci 2021; 1(1):1\u201341.","DOI":"10.21608\/sjpms.2021.190417"},{"key":"169306_B6","unstructured":"Alessi K, Patel P, Parmar M. Fosinopril. In: StatPearls [Internet] 2024 Jan 31. StatPearls Publishing."},{"key":"169306_B7","doi-asserted-by":"crossref","unstructured":"Al-Sanea MM, Abdelgawad MA, Alharbi KS, et al. Simultaneous analysis of several antihypertensive drugs in different combinations: Application for determination of drug degradation products and process impurities. Microchem J 2021; 166:106203.","DOI":"10.1016\/j.microc.2021.106203"},{"key":"169306_B8","doi-asserted-by":"crossref","unstructured":"Snauwaert E, Vande Walle J, De Bruyne P. Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review. Arch Dis Child 2017; 102(1):63\u201371.","DOI":"10.1136\/archdischild-2016-310582"},{"key":"169306_B9","doi-asserted-by":"crossref","unstructured":"Chu PY, Campbell MJ, Miller SG, et al. Anti-hypertensive drugs in children and adolescents. World J Cardiol 2014; 6(5):234.","DOI":"10.4330\/wjc.v6.i5.234"},{"key":"169306_B10","doi-asserted-by":"crossref","unstructured":"De Paepe B, Verstraeten VL, De Potter CR, et al. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol 2002; 117(1):13\u20139.","DOI":"10.1007\/s00418-001-0356-0"},{"key":"169306_B11","doi-asserted-by":"crossref","unstructured":"Sj\u00f6berg T, Garc\u00eda Rodr\u00edguez LA, Lindblad M. Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin Gastroenterol Hepatol 2007; 5(10):1160\u20131166.e1.","DOI":"10.1016\/j.cgh.2007.08.005"},{"key":"169306_B12","doi-asserted-by":"crossref","unstructured":"Christian JB, Lapane KL, Hume AL, et al. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. JNCI J Natl Cancer Inst 2008; 100(17):1223\u201332.","DOI":"10.1093\/jnci\/djn262"},{"key":"169306_B13","doi-asserted-by":"crossref","unstructured":"Saber S, Mahmoud AAA, Goda R, et al. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. Toxicol Lett 2018; 295:32\u201340.","DOI":"10.1016\/j.toxlet.2018.05.036"},{"key":"169306_B14","unstructured":"Li LinLin, Chaolumen Qiqige. The efficacy of tripterygium glycosides combined with fosinopril in treatment of HSPN in children. Genomics Appl Biol 2017; 36(2):466\u201371."},{"key":"169306_B15","doi-asserted-by":"crossref","unstructured":"Choudhary R, Kapoor MS, Singh A, et al. Therapeutic targets of renin-angiotensin system in ocular disorders. J Curr Ophthalmol 2017; 29(1):7\u201316.","DOI":"10.1016\/j.joco.2016.09.009"},{"key":"169306_B16","doi-asserted-by":"crossref","unstructured":"Mehta A, Iyer L, Parmar S, et al. Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Can J Physiol Pharmacol 2010; 88(5):595\u2013600.","DOI":"10.1139\/Y10-026"},{"key":"169306_B17","doi-asserted-by":"crossref","unstructured":"Hnin HM, Stef\u00e1nsson E, Loftsson T, et al. Physicochemical and stability evaluation of topical niosomal encapsulating fosinopril\/\u03b3-cyclodextrin complex for ocular delivery. Pharmaceutics 2022; 14(6):1147.","DOI":"10.3390\/pharmaceutics14061147"},{"key":"169306_B18","doi-asserted-by":"crossref","unstructured":"Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002; 41(3):207\u201324.","DOI":"10.2165\/00003088-200241030-00005"},{"key":"169306_B19","doi-asserted-by":"crossref","unstructured":"Shinde KP, Rajmane AD. A review UV method development and validation. Asian J Pharm Anal 2023; 13(2):122\u201330.","DOI":"10.52711\/2231-5675.2023.00021"},{"key":"169306_B20","unstructured":"Fosinopril sodium. In: European Directorate for the Quality of Medicines & HealthCare (EDQM) (2023). European Pharmacopoeia 11th ed. p. 2849."},{"key":"169306_B21","doi-asserted-by":"crossref","unstructured":"Ozkan A, Sen HM, Sehitoglu I, et al. Neuroprotective effect of humic acid on focal cerebral ischemia injury: an experimental study in rats. Inflammation 2015; 38(1):32\u20139.","DOI":"10.1007\/s10753-014-0005-0"},{"key":"169306_B22","doi-asserted-by":"crossref","unstructured":"Jan\u010di\u0107 B, Medenica M, Ivanovi\u0107 D, et al. Microemulsion liquid chromatographic method for characterisation of fosinopril sodium and fosinoprilat separation with chemometrical support. Anal Bioanal Chem 2005; 383(4):687\u201394.","DOI":"10.1007\/s00216-005-0074-x"},{"key":"169306_B23","doi-asserted-by":"crossref","unstructured":"Jan\u010di\u0107 B, Medenica M, Ivanovi\u0107 D, et al. Monitoring of fosinopril sodium impurities by liquid chromatography\u2013mass spectrometry including the neural networks in method evaluation. J Chromatogr A 2008; 1189(1-2):366\u201373.","DOI":"10.1016\/j.chroma.2007.11.076"},{"key":"169306_B24","doi-asserted-by":"crossref","unstructured":"Jemal M, Huang M, Mao Y, et al. Liquid chromatography\/electrospray tandem mass spectrometry method for the quantitation of fosinoprilat in human serum using automated 96-well solid-phase extraction for sample preparation. Rapid Commun Mass Spectrom 2000; 14(12):1023\u20138.","DOI":"10.1002\/1097-0231(20000630)14:12<1023::AID-RCM983>3.3.CO;2-B"},{"key":"169306_B25","doi-asserted-by":"crossref","unstructured":"Jemal M, Mulvana DE. Liquid chromatographic\u2013electrospray tandem mass spectrometric method for the simultaneous quantitation of the prodrug fosinopril and the active drug fosinoprilat in human serum. J Chromatogr B Biomed Sci App 2000; 739(2):255\u201371.","DOI":"10.1016\/S0378-4347(99)00551-4"},{"key":"169306_B26","doi-asserted-by":"crossref","unstructured":"Jan\u010di\u0107 B, Ivanovic D, Medenica M, et al. Development of liquid chromatographic method for fosinoprilat determination in human plasma using microemulsion as eluent. J Chromatogr A 2005; 1088(1\u20132):187\u201392.","DOI":"10.1016\/j.chroma.2005.05.038"},{"key":"169306_B27","doi-asserted-by":"crossref","unstructured":"Cui S, Feng F, Ma M, et al. Development and validation of liquid chromatography\u2013tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma. J Chromatogr B 2007; 854(1\u20132):143\u201351.","DOI":"10.1016\/j.jchromb.2007.04.019"},{"key":"169306_B28","doi-asserted-by":"crossref","unstructured":"Bhavna, Ojha A, Bhargava S. International Council for Harmonisation (ICH) guidelines. In: Regulatory Affairs in the Pharmaceutical Industry [Internet]. Elsevier; 2022 [cited 2025 Jul 27]. p. 47\u201374. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128222119000083","DOI":"10.1016\/B978-0-12-822211-9.00008-3"},{"key":"169306_B29","unstructured":"Gherman S, Zavastin D, Dorneanu V. Development and validation of UV spectrophotometric method for determination of enalapril maleate from commercial dosage forms. Farmacia 2015; 63(69):934\u20137."},{"key":"169306_B30","doi-asserted-by":"crossref","unstructured":"Sri KB, Fatima MS, Sumakanth M. Development and validation of a stability-indicating UV spectroscopic method for baricitinib in bulk and formulation. Pharm Sci Drug Des 2022; 2(1):8\u201313.","DOI":"10.51847\/JxHXkcB6tD"},{"key":"169306_B31","doi-asserted-by":"crossref","unstructured":"Rangelov VK, Ivanova S, Nalbantova V, et al. Development and validation of an LC-PDA method for detection of the natural \u03b22 agonist higenamine. Pharmacia 2025; 72:1\u20137.","DOI":"10.3897\/pharmacia.72.e151153"},{"key":"169306_B32","unstructured":"Harsha KM, Suresha DN, Naveen Kumar GS. Development and validation of a UV spectroscopic method for analysis of bilastine in bulk and tablet form. World J Pharm Res 2025; 14(13):1341\u20139."}],"container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"https:\/\/foliamedica.bg\/article\/169306\/download\/pdf\/","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article\/169306\/download\/xml\/","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliamedica.bg\/article_preview.php?id=169306&skip_redirect=1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:08:28Z","timestamp":1771934908000},"score":1,"resource":{"primary":{"URL":"https:\/\/foliamedica.bg\/article\/169306\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.3897\/folmed.68.e169306","relation":{},"ISSN":["1314-2143","0204-8043"],"issn-type":[{"value":"1314-2143","type":"electronic"},{"value":"0204-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"e169306"}}